NCT03711058: Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS Colorectal Cancer)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Part 1 of the dose escalation phase (not the expansion phase); Patients must have microsatellite stable (MSS) solid tumor
Exclusions: Patients with known central nervous system (CNS) metastases and/or leptomeningeal disease; Patients with prior treatment of immunotherapy agents and/or PI3K inhibitors

Comments are closed.

Up ↑